INNOVIVE Pharmaceuticals Appoints Angelo De Caro to Its Board of Directors and Audit Committee
16 February 2007 - 9:46AM
PR Newswire (US)
NEW YORK, Feb. 15 /PRNewswire-FirstCall/ -- INNOVIVE
Pharmaceuticals, Inc. (OTC:IVPH) (BULLETIN BOARD: IVPH) today
announced that Angelo De Caro has been appointed to serve on the
Company's Board of Directors and Audit Committee. Mr. De Caro
brings to the Company more than four decades of experience in
finance and operations. He has served as Chairman and CEO of
Patriot National Bancorp, Inc., since 2001 and as a Director of the
company since 1999. Additionally, during more than 16 years with
Goldman Sachs & Co., he oversaw various operations departments
including finance and taxation, as well as audit and risk
management functions. He served as General Partner and Senior
Financial Officer at Goldman Sachs for more than 10 years and was a
member of the Executive Committee of the company's Swiss Private
Bank. "We are fortunate to bring Angelo De Caro's depth of
financial and operations expertise to Innovive's Board of
Directors," said Steven Kelly, President and CEO of INNOVIVE
Pharmaceuticals. "His perspectives and extensive network within the
banking and finance communities will be extremely valuable as we
advance our portfolio of novel oncology and hematology
therapeutics." In addition to his tenures with Patriot National
Bancorp and Goldman Sachs, Mr. De Caro served as Vice President and
Senior Financial Officer at Loeb Rhoades, Inc., an investment
banking firm. He was educated at Long Island University and holds
an M.S. in accounting and taxation, and a B.S. in accounting. About
INNOVIVE Pharmaceuticals INNOVIVE Pharmaceuticals, Inc. acquires,
develops and commercializes novel therapeutics addressing
significant unmet medical needs in the fields of oncology and
hematology. The company has four drug programs in clinical
development: Tamibarotene, INNO-406, INNO-206, and INNO-305, for
the treatment of acute promyelocytic leukemia, chronic myelogenous
leukemia, small cell lung cancer, and acute myelogenous leukemia,
respectively. For additional information, visit
http://www.innovivepharma.com/. DATASOURCE: INNOVIVE
Pharmaceuticals, Inc. CONTACT: Steve Kelly, President and CEO of
INNOVIVE Pharmaceuticals, +1-212-716-1820; or Rachel Lipsitz, Media
& Investor Relations of Porter Novelli Life Sciences,
+1-619-849-5378, for INNOVIVE Pharmaceuticals, Inc. Web site:
http://www.innovivepharma.com/
Copyright